| Medical and Health Sciences | Lifetime | 209 | US 113 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 187 | US 71 | 99.96 |
| Pulmonary and Respiratory Medicine | Lifetime | 14 | US 12 | 99.98 |
| Surgery | Lifetime | 36 | US 22 | 99.97 |
| Oncology | Lifetime | 85 | US 46 | 99.85 |
| Gastroenterology | Lifetime | 176 | US 75 | 97.71 |
| Cancer Research | Lifetime | 808 | US 415 | 94.12 |
| Surgery | 2021-2025 | 27 | US 10 | 99.84 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 24 | US 8 | 99.89 |
| Oncology | 2021-2025 | 62 | US 23 | 99.68 |
| Gastroenterology | 2021-2025 | 82 | US 27 | 94.00 |
| Gastric Cancer Management and Outcomes | Lifetime | 2 | US 1 | 99.99 |
| Esophageal Cancer Research and Treatment | Lifetime | 1 | US 1 | 99.98 |
| Metastasis and carcinoma case studies | Lifetime | 1 | US 1 | 99.96 |
| Colorectal Cancer Treatments and Studies | Lifetime | 9 | US 6 | 99.91 |
| Colorectal and Anal Carcinomas | Lifetime | 7 | US 2 | 99.87 |
| Esophageal and GI Pathology | Lifetime | 10 | US 7 | 99.89 |
| Gastrointestinal Tumor Research and Treatment | Lifetime | 5 | US 3 | 99.95 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 71 | US 43 | 99.73 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 92 | US 44 | 99.47 |
| Neuroendocrine Tumor Research Advances | Lifetime | 106 | US 50 | 99.47 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 207 | US 121 | 99.48 |
| Lung Cancer Treatments and Mutations | Lifetime | 233 | US 128 | 99.39 |
| Helicobacter pylori-related gastroenterology studies | Lifetime | 167 | US 60 | 99.15 |
| Cancer Treatment and Pharmacology | Lifetime | 234 | US 130 | 99.28 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 263 | US 128 | 99.15 |
| Cancer-related gene regulation | Lifetime | 209 | US 110 | 98.64 |
| Neuroblastoma Research and Treatments | Lifetime | 244 | US 128 | 98.48 |
| HER2/EGFR in Cancer Research | Lifetime | 310 | US 149 | 98.65 |
| Peptidase Inhibition and Analysis | Lifetime | 636 | US 290 | 97.88 |
| Cancer Mechanisms and Therapy | Lifetime | 278 | US 129 | 97.13 |
| Cancer Cells and Metastasis | Lifetime | 762 | US 334 | 97.07 |
| Hippo pathway signaling and YAP/TAZ | Lifetime | 148 | US 70 | 96.60 |
| Genetic factors in colorectal cancer | Lifetime | 926 | US 384 | 97.13 |
| Lung Cancer Research Studies | Lifetime | 952 | US 388 | 96.97 |
| Colorectal Cancer Surgical Treatments | Lifetime | 849 | US 249 | 96.48 |
| Cancer therapeutics and mechanisms | Lifetime | 999 | US 482 | 95.44 |
| Multiple and Secondary Primary Cancers | Lifetime | 527 | US 234 | 95.06 |
| Intraperitoneal and Appendiceal Malignancies | Lifetime | 523 | US 204 | 94.29 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 1 | US 1 | 99.92 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 5 | US 1 | 99.93 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 5 | US 1 | 99.79 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 73 | US 24 | 99.71 |
| Metastasis and carcinoma case studies | 2021-2025 | 10 | US 1 | 98.77 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 104 | US 34 | 98.82 |
| Barrier Structure and Function Studies | 2021-2025 | 12 | US 5 | 95.37 |
| Peptidase Inhibition and Analysis | 2021-2025 | 150 | US 42 | 96.54 |
| HER2/EGFR in Cancer Research | 2021-2025 | 139 | US 50 | 97.96 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 251 | US 86 | 96.76 |
| Cancer Cells and Metastasis | 2021-2025 | 216 | US 63 | 93.06 |
| Esophageal and GI Pathology | 2021-2025 | 696 | US 188 | 91.50 |
| Cancer Research and Treatments | 2021-2025 | 394 | US 116 | 86.72 |
| Colorectal and Anal Carcinomas | 2021-2025 | 857 | US 208 | 83.63 |
| Hippo pathway signaling and YAP/TAZ | 2021-2025 | 483 | US 116 | 66.81 |
| Chromatin Remodeling and Cancer | 2021-2025 | 745 | US 301 | 59.41 |
| Fibroblast Growth Factor Research | 2021-2025 | 969 | US 272 | 55.51 |
